Wnt (canonical and non canonical) pathways in breast carcinoma with extensive vascular invasion and inflammatory breast carcinoma.


Journal

Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 06 11 2020
revised: 12 01 2021
accepted: 15 01 2021
pubmed: 8 2 2021
medline: 4 11 2021
entrez: 7 2 2021
Statut: ppublish

Résumé

Breast carcinoma with extensive peritumoral vascular invasion (ePVI-BC) is a cancer with massive vascular invasion (>10) detected in more than one slide. This neoplasm shows clinic-pathological affinity with inflammatory breast carcinoma (IBC). In this paper we evaluate their biological relationship through the study of surrogate markers (β-catenin and NFAT5) of Canonical (cWnt) and non-canonical (nWnt) Wnt pathways activation. By immunoistochemistry, we investigate β-catenin and NFAT5 in 39 IBC, 74 ePVI-BC and 84 control cases (CG-BC). cWnt was activated in 100 % of ePVI-BC, in 64 % of IBC and 10 % of CG-BC. nWnt was activated in 20 % of ePVI-BC, 50 % of IBC and 1% of CG-BC. The prognosis of carcinomas with nWnt activated was poor similar to IBC. The statistical analysis evidences as both the pathways are synergistic in malignant progression and survival time. β-catenin show an important association with prognostic factors and NFAT5 shows a relevant prognostic role on OS (p = 1.5*10 Canonical Wnt pathway is involved in malignant progression with dominant role for vascular invasion whereas non canonical Wnt pathway plays an important role on survival time including the capacity to identify carcinomas with IBC-like prognosis. Furthermore ePVI may represent a "prodromal form of IBC" as demonstrated by its clinicopathological and biological similarity with IBC.

Sections du résumé

BACKGROUND BACKGROUND
Breast carcinoma with extensive peritumoral vascular invasion (ePVI-BC) is a cancer with massive vascular invasion (>10) detected in more than one slide. This neoplasm shows clinic-pathological affinity with inflammatory breast carcinoma (IBC). In this paper we evaluate their biological relationship through the study of surrogate markers (β-catenin and NFAT5) of Canonical (cWnt) and non-canonical (nWnt) Wnt pathways activation.
METHODS METHODS
By immunoistochemistry, we investigate β-catenin and NFAT5 in 39 IBC, 74 ePVI-BC and 84 control cases (CG-BC).
RESULTS RESULTS
cWnt was activated in 100 % of ePVI-BC, in 64 % of IBC and 10 % of CG-BC. nWnt was activated in 20 % of ePVI-BC, 50 % of IBC and 1% of CG-BC. The prognosis of carcinomas with nWnt activated was poor similar to IBC. The statistical analysis evidences as both the pathways are synergistic in malignant progression and survival time. β-catenin show an important association with prognostic factors and NFAT5 shows a relevant prognostic role on OS (p = 1.5*10
CONCLUSIONS CONCLUSIONS
Canonical Wnt pathway is involved in malignant progression with dominant role for vascular invasion whereas non canonical Wnt pathway plays an important role on survival time including the capacity to identify carcinomas with IBC-like prognosis. Furthermore ePVI may represent a "prodromal form of IBC" as demonstrated by its clinicopathological and biological similarity with IBC.

Identifiants

pubmed: 33550148
pii: S0344-0338(21)00008-X
doi: 10.1016/j.prp.2021.153347
pii:
doi:

Substances chimiques

Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

153347

Informations de copyright

Copyright © 2021. Published by Elsevier GmbH.

Auteurs

A Remo (A)

Pathology Unit, ULSS9 "Scaligera" and Breast Unit (Eusoma's Certification n°1030/00), Verona, Italy. Electronic address: remino76@yahoo.it.

S Sina (S)

Pathology Unit, ULSS9 "Scaligera" and Breast Unit (Eusoma's Certification n°1030/00), Verona, Italy.

S Barbi (S)

Department of Pathology and Diagnosis, University of Verona, Verona, Italy.

I Simeone (I)

Center for Genomic Science of IIT@SEMM - Istituto Italiano di Tecnologia, Milan, Italy; Department of Science and Technology, University of Sannio, Benevento, Italy.

J Insolda (J)

Pathology Unit, ULSS9 "Scaligera" and Breast Unit (Eusoma's Certification n°1030/00), Verona, Italy.

P Parcesepe (P)

Department of Pathology and Diagnosis, University of Verona, Verona, Italy.

G Giordano (G)

U.O.C. Oncologia Medica, Ospedali Riuniti Azienda Ospedaliera Universitaria, 71122, Foggia, Italy.

L Cerulo (L)

Department of Science and Technology, University of Sannio, Benevento, Italy; Bioinformatics Laboratory, BIOGEM, Ariano Irpino, Avellino, Italy.

M Ceccarelli (M)

Department of Science and Technology, University of Sannio, Benevento, Italy; Bioinformatics Laboratory, BIOGEM, Ariano Irpino, Avellino, Italy.

F Fiorica (F)

Radiotherapy Unit, ULSS9 "Scaligera"and Breast Unit (Eusoma's Certification n°1030/00), Verona, Italy.

A Bonetti (A)

Oncology Unit, ULSS9 "Scaligera"and Breast Unit (Eusoma's Certification n°1030/00), Verona, Italy.

M Pancione (M)

Department of Science and Technology, University of Sannio, Benevento, Italy.

E Manfrin (E)

Department of Pathology and Diagnosis, University of Verona, Verona, Italy. Electronic address: erminia.manfrin@univr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH